Storage of thawed plasma for a liquid plasma bank: Impact of temperature and methylene blue pathogen inactivation

Transfusion

Volumn 52, Issue 3, 2012, Pages 529-536

  Thiele, Thomas ^a,b   Kellner, Sarah ^a,b   Hron, Gregor ^a,b   Wasner, Christina ^a,b   Nauck, Matthias ^a,b   Zimmermann, Kathrin ^a,b   Wessel, Antje ^a,b   Warkentin, Theodore E ^a,b   Greinacher, Andreas ^a,b   Selleng, Kathleen ^a,b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; FRESH FROZEN PLASMA; METHYLENE BLUE; PROTEIN C; PROTEIN S; PROTHROMBIN; VON WILLEBRAND FACTOR;

APHERESIS; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD STORAGE; CONTROLLED STUDY; HUMAN; PLASMA; ROOM TEMPERATURE; STORAGE TEMPERATURE; TEMPERATURE DEPENDENCE; THAWING;

BLOOD BANKS; BLOOD COAGULATION; BLOOD COMPONENT REMOVAL; BLOOD PRESERVATION; BLOOD-BORNE PATHOGENS; COLD TEMPERATURE; CRYOPRESERVATION; ENZYME INHIBITORS; HUMANS; LIGHT; METHYLENE BLUE; PLASMA;

EID: 84858292862     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03317.x     Document Type: Article

References (29)

1. Steil L, Thiele T, Hammer E, Bux J, Kalus M, Völker U, Greinacher A,. Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain. Transfusion 2008; 48: 2356-63.
2. Circular of information for the use of human blood and blood components by AABB ARC, America's Blood Centers, and the Armed Services Blood Program; as of Oct. 21, 2009
3. Downes KA, Wilson E, Yomtovian R, Sarode R,. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001; 41: 570. (Pubitemid 32378114)
4. Roth WK,. Quarantine plasma: quo vadis? Transfus Med Hemother 2010; 37: 118-22.
5. Seghatchian J, Struff W, Reichenberg S,. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011; 38: 55-64.
6. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Published by the Board of the German Medical Association (Bundesärztekammer) on the recommendadtion of the Scientific Advisory Board. Cologne: Deutscher Îrzte-Verlag; 2010.
7. Schoenfeld H, Pruss A, Keller M, Schuster M, Meinck K, Neuner B, von Heymann C,. Lyophilised plasma: evaluation of clotting factor activity over 6 days after reconstitution for transfusion. J Clin Pathol 2010; 63: 726-30.
8. von Heymann C, Keller MK, Spies C, Schuster M, Meinck K, Sander M, Wernecke KD, Kiesewetter H, Pruss A,. Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. Transfusion 2009; 49: 913-20.
9. Cardigan R, Lawrie AS, Mackie IJ, Williamson LM,. The quality of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion 2005; 45: 1342-8. (Pubitemid 41647802)
10. Alhumaidan H, Cheves T, Holme S, Sweeney J,. Stability of coagulation factors in plasma prepared after a 24-hour room temperature hold. Transfusion 2010; 50: 1934-42.
11. Lamboo M, Poland DC, Eikenboom JC, Harvey MS, Groot E, Brand A, de Vries RR,. Coagulation parameters of thawed fresh-frozen plasma during storage at different temperatures. Transfus Med 2007; 17: 182-6. (Pubitemid 46897120)
12. Sidhu RS, Le T, Brimhall B, Thompson H,. Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1-6 degrees C for five days. J Clin Apher 2006; 21: 224-6. (Pubitemid 46034435)
13. Yazer MH, Cortese-Hassett A, Triulzi DJ,. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion 2008; 48: 2525-30.
14. Bostrom F, Sjodahl M, Wehlin L, Egberg N, Lundahl J,. Coagulation parameters in apheresis and leukodepleted whole-blood plasma during storage. Transfusion 2007; 47: 460-3.
15. Scott E, Puca K, Heraly J, Gottschall J, Friedman K,. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. Transfusion 2009; 49: 1584-91.
16. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD,. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47: 120-5. (Pubitemid 46006319)
17. Norda R, Knutson F, Berseus O, Akerblom O, Nilsson-Ekdahl K, Stegmayr B, Nilsson B,. Unexpected effects of donor gender on the storage of liquid plasma. Vox Sang 2007; 93: 223-8. (Pubitemid 47373994)
18. Matijevic N, Kostousov V, Wang YW, Wade CE, Wang W, Letourneau P, Hartwell E, Kozar R, Ko T, Holcomb JB,. Multiple levels of degradation diminish hemostatic potential of thawed plasma. J Trauma 2011; 70: 71-9; discussion 9-80.
19. Plasma for therapeutic use. In: Cross-sectional guidelines for therapy with blood components and plasma derivatives: plasma in therapeutic use. Published by the Board of the German Medical Association (Bundesä rztekammer) on the recommendadtion of the Scientific Advisory Board. Transfus Med Hemother 2009; 36: 388-97.
20. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV,. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001; 11: 31-6. (Pubitemid 32180319)
21. Zeiler T, Riess H, Wittmann G, Hintz G, Zimmermann R, Müller C, Heuft HG, Huhn D,. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994; 34: 685-9. (Pubitemid 24270113)
22. Garwood M, Cardigan RA, Drummond O, Hornsey VS, Turner CP, Young D, Williamson LM, Prowse CV,. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003; 43: 1238-47. (Pubitemid 37082684)
23. Osselaer JC, Debry C, Goffaux M, Pineau J, Calomme G, Dubuc E, Chatelain B, Vandendaele MC, Hsu J, Rheinschmidt M, Lin L,. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48: 108-17.
24. Cardigan R, Philpot K, Cookson P, Luddington R,. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009; 49: 696-703.
25. Rapaport SI,. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-65. (Pubitemid 19060512)
26. Chand HS, Foster DC, Kisiel W,. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost 2005; 94: 1122-30. (Pubitemid 41819605)
27. Lwaleed BA, Bass PS,. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208: 327-39. (Pubitemid 43210519)
28. del Rio-Garma J, Alvarez-Larran A, Martinez C, Muncunill J, Castellà D, de la Rubia J, Zamora C, Corral M, Viejo A, Peña F, Rodríguez-Vicente P, Contreras E, Arbona C, Ramírez C, Garcia-Erce JA, Alegre A, Mateo J, Pereira A,. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39-45.
29. Koerner K, Stampe D,. [Stability of blood coagulation factors in deep frozen fresh plasma by storage at -20 degrees C and -40 degrees C]. Infusionsther Klin Ernahr 1984; 11: 46-50. (Pubitemid 14196255)